2,3-dimethyl-1-buthyl fluoride | 62127-35-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 2,3-dimethyl-1-buthyl fluoride
• 英文别名: 1-Fluoro-2,3-dimethylbutane
• CAS: 62127-35-9
• 化学式: C₆H₁₃F
• 分子量: 104.168
• InChiKey: RQZSTHDLPZGOMA-UHFFFAOYSA-N

物化性质

• 熔点：
  -103.67°C (estimate)
• 沸点：
  87.88°C (estimate)
• 密度：
  0.8125 (estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,3-二甲基-1-丁烯 在 HF-melamine 、 氢氟酸 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以85%的产率得到2,3-dimethyl-1-buthyl fluoride
  参考文献：
  名称：

  三聚氰胺-氟化氢溶液。一种高效便捷的烯烃氟化氢试剂

  摘要：

  已发现 14% (w/w) 三聚氰胺在 86% (w/w) 氟化氢中的溶液是稳定的，并且比其他有机胺 - 氟化氢试剂更方便和有效的烯烃氢氟化试剂。

  DOI：

  10.1246/cl.1983.1135

文献信息

• Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
  申请人：Smith Brian

  公开号：US20070142357A1

  公开（公告）日：2007-06-21

  The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders.

  本发明涉及某些1-取代-2,3,4,5-四氢-3-苯并咪唑衍生物，其为5HT2C受体调节剂。因此，本发明化合物可用于预防或治疗与5HT2C受体相关的疾病、病况或障碍，如肥胖症及相关疾病。
• ANTIVIRAL COMPOUNDS
  申请人：Guo Hongyan

  公开号：US20120264711A1

  公开（公告）日：2012-10-18

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及抗病毒化合物、含有这种化合物的组合物、包括给予这种化合物的治疗方法，以及用于制备这种化合物的过程和中间体。
• Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10253018B2

  公开（公告）日：2019-04-09

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明公开了式 (I) 化合物或其药学上可接受的盐、酯、立体异构体、同分异构体、溶液剂、水合物或其组合： 其抑制与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾病、心血管疾病相关的凋亡信号调节激酶 1 (ASK-1)。本发明进一步涉及包含上述化合物的药物组合物，用于给患有 ASK-1 相关疾病的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 ASK-1 相关疾病的方法。本发明特别涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）。
• METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20200325177A1

  公开（公告）日：2020-10-15

  Disclosed herein, inter alia, are methods of making and using streptogramin compositions.
• APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20200331890A1

  公开（公告）日：2020-10-22

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).